Recent Finacing
Recent Raise
Carmot Therapeutics applies its Chemotype Evolution platform to discover peptide and small‑molecule therapeutics for metabolic diseases and oncology, advancing dual GLP‑1/GIP modulators (CT‑868, CT‑388) and CT‑996.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Carmot Therapeutics.
